Related Experiment Video
Updated: May 10, 2025

Generation of High-Throughput Three-Dimensional Tumor Spheroids for Drug Screening
Published on: September 5, 2018
Two first-generation KRAS inhibitor safety profiles: a disproportionality analysis of individual reports from the FDA
Ying Zhang1, Shuhua Tong1, Li Wan1
1Department of Pharmacy, Maternal and Child Health Hospital of Hubei Province, Tongji Medical College, Huazhong University of Science and Technology, China.
Background:
First-generation KRAS inhibitors, sotorasib and adagrasib, are approved for treating non-small cell lung cancer and colorectal cancer with specific KRAS mutations. This study analyzed data from FAERS database to evaluate adverse events (AEs) associated with KRAS inhibitors.
Research Design And Methods:
Four disproportionality analysis methods were applied to measure risk signals: reporting odds ratio (ROR), proportional reporting ratio (PRR), bayesian confidence propagation neural network (BCPNN), and multi-item gamma poisson shrinker (MGPS) algorithms.
Results:
Between Q2 2021 and Q1 2024, 5,580 AEs in 2,958 reports on sotorasib or adagrasib were identified. Most patients were 45 and above, with a median age of 67. After meeting four algorithms' criteria, sotorasib and adagrasib retained 43 and 18 disproportionate priority items (PTs), respectively. Common AEs were diarrhea, hepatotoxicity, and pneumonitis. Unexpected important AEs included pericardial effusion, colitis, and pancreatitis associated with sotorasib; seizure, encephalopathy, unresponsiveness to stimuli and disorientation with adagrasib. Most AEs emerged within the first month of treatment. The median time to onset was 50 days for sotorasib and 21 days for adagrasib.
Conclusions:
Our research revealed potential new AE signals and provided a comprehensive safety profile of KRAS inhibitors, emphasizing the importance of careful monitoring and supportive care.
Insights
First-generation KRAS inhibitors, sotorasib and adagrasib, show specific adverse events like diarrhea and hepatotoxicity. This analysis highlights the need for careful patient monitoring during cancer treatment.
Area of Science:
- Oncology
- Pharmacovigilance
- Drug Safety
Background:
- Sotorasib and adagrasib are approved first-generation KRAS inhibitors for specific cancers.
- This study evaluates adverse events (AEs) associated with these KRAS inhibitors using FAERS data.
Purpose of the Study:
- To assess the safety profile of sotorasib and adagrasib.
- To identify potential new adverse event signals for KRAS inhibitors.
Main Methods:
- Utilized the FAERS database for adverse event reporting.
- Applied four disproportionality analysis methods: ROR, PRR, BCPNN, and MGPS.
- Analyzed 5,580 AEs from 2,958 reports between Q2 2021 and Q1 2024.
Main Results:
- Identified 43 and 18 disproportionate reporting items for sotorasib and adagrasib, respectively.
- Common AEs included diarrhea, hepatotoxicity, and pneumonitis.
- Unexpected AEs such as pericardial effusion (sotorasib) and seizure (adagrasib) were noted, with most occurring within the first month of treatment.
Conclusions:
- The study provides a comprehensive safety profile for KRAS inhibitors.
- Highlights the emergence of new AE signals, underscoring the need for vigilant monitoring and supportive care in patients receiving these treatments.
More Related Videos
08:23Single Droplet Digital Polymerase Chain Reaction for Comprehensive and Simultaneous Detection of Mutations in Hotspot Regions
Published on: September 25, 2018
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
Related Concept Videos
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Drug Regulation
The Ras Gene
Ras is a...
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
Clinical Trials: Overview
Preclinical Development: Overview